Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9‐tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats
Authors:
- 17 September 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 170 (3) , 671-678
Abstract
Background and Purpose: The cannabinoid 1 (CB1) receptor inverse agonists/antagonists, rimonabant (SR141716, SR) and AM251, produce nausea and potentiate toxin‐induced nausea by inverse agonism (rather than antagonism) of the CB1 receptor. Here, we evaluated two phytocannabinoids, cannabidivarin (CBDV) and Δ9‐tetrahydrocannabivarin (THCV), for their ability to produce these behavioural effect characteristics of CB1 receptor inverse agonism in rats.Experimental Approach: In experiment 1, we investigated the potential of THCV and CBDV to produce conditioned gaping (measure of nausea‐induced behaviour) in the same manner as SR and AM251. In experiment 2, we investigated the potential of THCV and CBDV to enhance conditioned gaping produced by a toxin in the same manner as CB1 receptor inverse agonists.Key Results: SR (10 and 20 mg·kg−1) and AM251 (10 mg·kg−1) produced conditioned gaping; however, THCV (10 or 20 mg·kg−1) and CBDV (10 or 200 mg·kg−1) did not. At a subthreshold dose for producing nausea, SR (2.5 mg·kg−1) enhanced lithium chloride (LiCl)‐induced conditioned gaping, whereas Δ9‐tetrahydrocannabinol (THC, 2.5 and 10 mg·kg−1), THCV (2.5 or 10 mg·kg−1) and CBDV (2.5 or 200 mg·kg−1) did not; in fact, THC (2.5 and 10 mg·kg−1), THCV (10 mg·kg−1) and CBDV (200 mg·kg−1) suppressed LiCl‐induced conditioned gaping, suggesting anti‐nausea potential.Conclusions and Implications: The pattern of findings indicates that neither THCV nor CBDV produced a behavioural profile characteristic of CB1 receptor inverse agonists. As well, these compounds may have therapeutic potential in reducing nausea.Keywords
This publication has 54 references indexed in Scilit:
- Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleusBritish Journal of Pharmacology, 2011
- Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymesBritish Journal of Pharmacology, 2010
- A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodentsBritish Journal of Pharmacology, 2010
- Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in ratsBritish Journal of Pharmacology, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in miceBritish Journal of Pharmacology, 2010
- Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142European Neuropsychopharmacology, 2010
- Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113Pharmacology Biochemistry and Behavior, 2009
- The psychoactive plant cannabinoid, Δ9‐tetrahydrocannabinol, is antagonized by Δ8‐ and Δ9‐tetrahydrocannabivarin in micein vivoBritish Journal of Pharmacology, 2007